A Randomized, Open Label, Single Subcutaneous Dose 6x3 Crossover Study to Investigate the Relative Bioavailability Among Different Eutropin Formulations in Healthy Male Volunteers

Trial Profile

A Randomized, Open Label, Single Subcutaneous Dose 6x3 Crossover Study to Investigate the Relative Bioavailability Among Different Eutropin Formulations in Healthy Male Volunteers

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 24 Jul 2017

At a glance

  • Drugs Somatropin (Primary)
  • Indications Prader-Willi syndrome; Short stature; Somatotropin deficiency
  • Focus Pharmacokinetics
  • Sponsors LG Chem; LG Life Sciences
  • Most Recent Events

    • 18 Jul 2017 Planned End Date changed from 30 Jun 2017 to 30 Nov 2017.
    • 18 Jul 2017 Status changed from not yet recruiting to active, no longer recruiting.
    • 28 May 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top